{"id":20290,"date":"2012-10-01T12:02:02","date_gmt":"2012-10-01T12:02:02","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=20290"},"modified":"2019-01-10T16:22:28","modified_gmt":"2019-01-10T16:22:28","slug":"us-guidelines-include-stribild-quad-as-alternative-rather-than-preferred-option-for-treatment-naive-adults","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/20290","title":{"rendered":"US guidelines include Stribild (Quad) as alternative rather than preferred option for treatment naive adults (2012)"},"content":{"rendered":"<p><strong>Shortly after FDA approval of the new once-daily single-pill formulation of elvitegravir\/cobicistat\/tenofovir\/emtricitabine (Stribild) the US HHS guideline panel issued a statement on how this combination has been assessed in its recommendations for treatment naive adult patients.<\/strong><\/p>\n<p>The included the recommendation for elvitegravir 150 mg \/ cobicistat 150 mg \/ tenofovir 300 mg \/ emtricitabine 200 mg once daily (with food) as an &#8220;alternative&#8221; regimen for ART-naive HIV-infected patients with CrCl &gt;70 mL\/min. The recommendation was rated BI (moderate strength recomendation, based on results from randomised clinical trials).<\/p>\n<p>Factors behind the decision not to make this a &#8220;preferred&#8221; option included &#8220;a significant potential for drug-drug interactions, the availability of only 48 weeks of safety data, usage limited to individuals with pre-treatment CrCl &gt;70 mL\/min, a possible increased risk of proximal renal tubulopathy, limited data in patients with advanced HIV disease and in women, and the need for the drug to be taken with food&#8221;.<\/p>\n<p>Reference:<\/p>\n<p>HHS Panel Statement. HHS panel on antiretroviral guidelines for adults and adolescents recommends a fixed-dose combination product of elvitegravir\/cobicistat\/tenofovir\/emtricitabine as an alternative regimen in antiretroviral treatment-naive Individuals with HIV-1 infection. (18 September, 2012).<\/p>\n<p><a href=\"http:\/\/aidsinfo.nih.gov\/contentfiles\/AdultARVStatementOnEVG_COBI_TDF_FTC.pdf\" rel=\"noopener\">http:\/\/aidsinfo.nih.gov\/contentfiles\/AdultARVStatementOnEVG_COBI_TDF_FTC.pdf<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shortly after FDA approval of the new once-daily single-pill formulation of elvitegravir\/cobicistat\/tenofovir\/emtricitabine (Stribild) the US HHS guideline panel issued a statement on how this combination has been assessed in its recommendations for treatment naive adult patients. The included the recommendation &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[23],"tags":[],"class_list":["post-20290","post","type-post","status-publish","format-standard","hentry","category-guidelines"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/20290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=20290"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/20290\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=20290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=20290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=20290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}